AstraZeneca to acquire CinCor in nearly $2b deal - European Pharmaceutical Review

Retrieved on: 2023-01-09 20:13:25

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca to acquire CinCor in nearly $2b deal - European Pharmaceutical Review. View article details on hiswai:

Excerpt

For a transaction value of nearly $2b, AstraZeneca is set to acquire CinCor Pharma, Inc., including rights to hypertension drug baxdrostat.

Article found on: www.europeanpharmaceuticalreview.com